HR 6001 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Veterans with ALS Reporting Act
To require the Secretary of Veterans Affairs to submit a report on risk reduction strategies to lower the incidence and prevalence of amyotrophic lateral sclerosis in veterans.
Summary
This bill would require the Secretary of Veterans Affairs to submit a report within one year to Congress on amyotrophic lateral sclerosis (ALS) in veterans, developed in consultation with the Centers for Disease Control and Prevention. The report must assess the incidence and prevalence of ALS among veterans, describe existing VA and CDC resources and support for veterans with ALS, identify any deficiencies in those resources, and propose strategies to reduce ALS incidence and prevalence among veterans. The report must also include strategies to help veterans with ALS participate in VA-sponsored clinical trials and research, as well as legislative recommendations to address ALS-related challenges for veterans. The bill requires the VA to track ALS prevalence in veterans using the CDC's ALS registry and biorepository, and to submit updated reports to Congress every three years.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Rep. Crow, Jason [D-CO-6] (D-CO)
9 cosponsors
- Rep. Bell, Wesley [D-MO-1] (D-MO)
- Rep. Calvert, Ken [R-CA-41] (R-CA)
- Rep. Fitzpatrick, Brian K. [R-PA-1] (R-PA)
- Rep. Harshbarger, Diana [R-TN-1] (R-TN)
- Rep. Johnson, Julie [D-TX-32] (D-TX)
- Rep. McBride, Sarah [D-DE-At Large] (D-DE)
- Rep. Quigley, Mike [D-IL-5] (D-IL)
- Rep. Riley, Josh [D-NY-19] (D-NY)
- Rep. Sewell, Terri A. [D-AL-7] (D-AL)
Money behind the sponsor
Top reported contributors to Jason Crow’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- HOLLAND & HART LLP $18,300
- PALANTIR TECHNOLOGIES $17,225
- UNITED LAUNCH ALLIANCE $16,500
- DISH NETWORK $14,200
- PALANTIR $7,600
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Jason Crow → · Outside spending →
Actions (6)
- Apr 16, 2026 Forwarded by Subcommittee to Full Committee by Voice Vote. · house
- Apr 16, 2026 Subcommittee Consideration and Mark-up Session Held · house
- Jan 13, 2026 Subcommittee Hearings Held · house
- Nov 17, 2025 Referred to the Subcommittee on Health. · house
- Nov 10, 2025 Referred to the House Committee on Veterans' Affairs. · house
- Nov 10, 2025 Introduced in House
More bills on these subjects (8)
Other bills that carry the most legislative subjects in common with this one (topical discovery — distinct from the procedural related bills above).
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
November 10, 2025
Mr. Crow (for himself, Mr. Calvert, Ms. Sewell, and Mr. Fitzpatrick) introduced the following bill; which was referred to the Committee on Veterans’ Affairs
A BILL
To require the Secretary of Veterans Affairs to submit a report on risk reduction strategies to lower the incidence and prevalence of amyotrophic lateral sclerosis in veterans.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Veterans with ALS Reporting Act”.
SEC. 2. REPORT ON AMYOTROPHIC LATERAL SCLEROSIS IN VETERANS.
(a) In General.—Not later than one year after the date of the enactment of this Act, the Secretary of Veterans Affairs, in consultation with the Director of the Centers for Disease Control and Prevention, shall submit to Congress a report on the incidence and prevalence of amyotrophic lateral sclerosis (commonly known as “ALS”). Such report shall include—
(1) an assessment of the incidence and prevalence of amyotrophic lateral sclerosis in veterans (as defined in section 101 of title 38, United States Code);
(2) a description of the resources and support that the the Centers for Disease Control and the Department of Veterans Affairs provides to veterans with amyotrophic lateral sclerosis;
(3) a description of any deficiencies in the resources and support described in paragraph (2);
(4) a strategy to develop and test risk reduction strategies intended to lower the incidence and prevalence of amyotrophic lateral sclerosis among veterans;
(5) a strategy to develop a pathway for veterans receiving amyotrophic lateral sclerosis care within Department of Veterans Affairs clinics to participate in clinical trials and research sponsored by the Department of Veterans Affairs; and
(6) any recommendations for the enactment of legislation to address the challenges or needs associated with lowering the incidence and prevalence of amyotrophic lateral sclerosis among veterans.
(b) Tracking of Amyotrophic Lateral Sclerosis in Members and Veterans.—The Secretary of Veterans Affairs shall track the prevalence of amyotrophic lateral sclerosis in veterans using the amyotrophic lateral sclerosis registry and biorepository of the Centers for Disease Control and Prevention.
(c) Subsequent Reports.—Not later than three years after the date of the enactment of this Act, and every three years thereafter, the Secretary of Veterans Affairs shall submit to Congress an update to the report required under subsection (a) and information on the prevalence of amyotrophic lateral sclerosis tracked under subsection (b). <all>
Comments